The first phase III trials of SBRT+/- Checkpoint inhibitors for stage 1 NSCLC

Corinne Faivre-Finn, Professor of Thoracic Radiation Oncology at the University of Manchester, shared a post by Drew Moghanaki, on X:

“Keynote 867, which investigated Pembrolizumab in stage I and II NSCLC after SBRT, was closed early due to futility.

This underscores the critical need for phase 3 trials, as promising phase 2 results do not always translate into clinical benefit in phase 3”

Quoting Drew Moghanaki‘s post:

“The first of these phase III trials has reported.”

Read further.
Source: Corinne Faivre-Finn/X and Drew Moghanaki/X

Dr. Drew Moghanaki, a Professor and Chief of Thoracic Oncology at the Department of Radiation Oncology, UCLA. He holds the Stanley Iezman and Nancy Stark Endowed Chair in Thoracic Radiation Oncology Research at the same university.

He specializes in treating lung cancer and other thoracic malignancies, focusing on advanced radiation therapy techniques like stereotactic body radiation therapy (SBRT), magnetic resonance-guided radiation therapy (MRgRT), and intensity-modulated radiation therapy (IMRT).